Horizon Therapeutics' Lupus Candidate Flunks Mid-Stage Study
Portfolio Pulse from Vandana Singh
Horizon Therapeutics' Phase 2 trial for daxdilimab, a candidate for treating Systemic Lupus Erythematosus (SLE), failed to meet its primary endpoint. The study did not show a significant difference between daxdilimab and placebo in terms of patient response and oral glucocorticoid dose reduction. No safety concerns were reported. Horizon's shares are down 0.42% premarket.
July 24, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Horizon Therapeutics' stock price may be negatively impacted in the short term due to the failure of its Phase 2 trial for daxdilimab.
The failure of a Phase 2 trial is a significant setback for any pharmaceutical company, as it indicates that the drug may not be as effective as hoped. This can lead to a decrease in investor confidence and a subsequent drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100